The latest information that came from Cellceutix Corp (OTCMKTS:CTIX)‘s front is the selection of independent directors and committee members. On Monday, the clinical state bio-pharma company disclosed that it has welcomed Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin on its board of independent directors and committee members.
New members on board
The company provided a brief account of the background of all the newly appointed independent directors in its note. It said that Dr. Schechter is currently serving at Florida Eye Microsurgical Institute as Director of Department of Cornea and External Disease. He has been affiliated with the Institute since 2005. Cellceutix Corp (OTCMKTS:CTIX) also noted that Dr. Schechter had co-founded Pediavision, which was established to save children’s eyesight. Pediavision has recently been sold, the press release noted.
Dr. Spektor, M.D., F.A.A.P. is a Head and Neck Surgeon and is also a Pediatric Otolaryngologist, according to the company furnished press release. Dr. Spektor has been serving The Center for Pediatric ENT – Head and Neck Surgery since 1995, the company briefed. Moving on to Mr. Tobin, Cellceutix Corp (OTCMKTS:CTIX) informed that he is currently Director at Digital Offering, where he heads the Research department. Mr. Tobin has been working with the merchant bank since October 2013 while he is also a Managing Partner at Tobin Tao & Company.
Additional information
Other than introducing the new faces on the Board, Cellceutix Corp (OTCMKTS:CTIX) also added that its presentations delivered at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) during April 25-April 28, 2015 at Copenhagen, Denmark will be made available on its website. The company had recently provided an update on its primary drug candidate ‘Briladicin’. The stock of Cellceutix Corp (OTCMKTS:CTIX) settled 1.72% higher at $2.95 as 206,000 shares changed hands during the previous trading session.
